Contract Research And Manufacturing Services (CRAMS) Business Report 2025: Market To Reach $211.4 Billion By 2030, Fueled By Growing Demand For Biologics And Biosimilars

(MENAFN- GlobeNewsWire - Nasdaq) Understand the significant growth trajectory of the Manufacturing Service segment, which is expected to reach US$126.8 Billion by 2030 with a CAGR of a 6.7%. The Research Service segment is also set to grow at 8.1% CAGR over the analysis period. Gain insights into the U.S. market, valued at $37.4 Billion in 2024, and China, forecasted to grow at an impressive 11.4% CAGR to reach $46.5 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Dublin, May 08, 2025 (GLOBE NEWSWIRE) -- The "Contract Research and Manufacturing Services (CRAMS) - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.
The global market for Contract Research and Manufacturing Services (CRAMS) was valued at US$138.9 Billion in 2024 and is projected to reach US$211.4 Billion by 2030, growing at a CAGR of 7.2% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The report includes the most recent global tariff developments and how they impact the Contract Research and Manufacturing Services (CRAMS) market.
Contract Research and Manufacturing Services (CRAMS) Market Trends and Drivers
Contract Research and Manufacturing Services (CRAMS) encompass a broad spectrum of outsourcing services provided by companies to the pharmaceutical and biotechnological sectors. CRAMS allow drug developers to delegate specific R&D processes and manufacturing tasks to external partners. These services cover a wide range of activities, from early-stage drug discovery, preclinical trials, and clinical research to large-scale commercial manufacturing and API (active pharmaceutical ingredient) production.

By leveraging CRAMS, pharmaceutical companies can significantly reduce capital investment and operational costs, streamline product development timelines, and enhance flexibility in managing the fluctuating demands of drug development and production. Moreover, CRAMS providers offer specialized expertise and advanced facilities that many pharmaceutical companies might not possess internally, making them an integral component of today's drug development landscape.
The CRAMS industry has adapted to meet the evolving needs of the global healthcare sector, focusing on flexibility, scalability, and state-of-the-art technological integration. As biopharmaceutical products become more complex, the demand for sophisticated and specialized manufacturing techniques has escalated. CRAMS providers have responded by investing in cutting-edge technologies such as continuous manufacturing and bioreactors, which are crucial for the production of biologics and advanced therapy medicinal products (ATMPs), including gene and cell therapies. This trend is supported by a move towards more personalized medicine approaches, which require the production of small batches of highly specialized drugs. Furthermore, CRAMS providers have developed strong regulatory expertise to navigate the complex and varying global regulatory landscapes, ensuring compliance and facilitating smoother market entries for new drugs.
The growth in the CRAMS market is driven by several factors, including the increasing complexity of pharmaceutical production, heightened cost pressures faced by drug developers, and a surge in the number of small to mid-size biotech companies. Technological advancements in drug development processes have necessitated the adoption of highly specialized manufacturing capabilities that many pharmaceutical companies do not have in-house. This has increased their reliance on CRAMS providers who possess the necessary technological infrastructure and expertise.

Additionally, the rising focus on cost-efficiency within the pharmaceutical industry has propelled companies to seek external partners that can provide economies of scale and scope in both research and production phases. Consumer behavior has also influenced the CRAMS market, particularly as there is an increasing demand for faster development and delivery of new therapies to the market, which CRAMS can facilitate. Moreover, the growth of the biologics sector, which requires distinct production environments and expertise, continues to drive the expansion of CRAMS, making it an essential component of the modern pharmaceutical supply chain.
Tariff Impact Analysis: Key Insights for 2025
Global tariff negotiations across 180+ countries are reshaping supply chains, costs, and competitiveness. This report reflects the latest developments as of April 2025 and incorporates forward-looking insights into the market outlook.
The analysts continuously track trade developments worldwide, drawing insights from leading global economists and over 200 industry and policy institutions, including think tanks, trade organizations, and national economic advisory bodies. This intelligence is integrated into forecasting models to provide timely, data-driven analysis of emerging risks and opportunities.

Report Features:

• Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030.
• In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
• Company Profiles: Coverage of players such as AbbVie Inc., Arch Pharmalabs Ltd., Calyx Chemicals and Pharmaceuticals Ltd., Globela Pharma Pvt. Ltd., Ind-Swift Laboratories Ltd. and more.
• Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

What's Included in This Edition:

• Tariff-adjusted market forecasts by region and segment
• Analysis of cost and supply chain implications by sourcing and trade exposure
• Strategic insights into geographic shifts

Buyers receive a free July 2025 update with:

• Finalized tariff impacts and new trade agreement effects
• Updated projections reflecting global sourcing and cost shifts
• Expanded country-specific coverage across the industry

Key Attributes:

Report Attribute	Details
No. of Pages	250
Forecast Period	2024 - 2030
Estimated Market Value (USD) in 2024	$138.9 Billion
Forecasted Market Value (USD) by 2030	$211.4 Billion
Compound Annual Growth Rate	7.2%
Regions Covered	Global

Key Topics Covered:
MARKET OVERVIEW

• Influencer Market Insights
• Tariff Impact on Global Supply Chain Patterns
• Global Economic Update
• Contract Research and Manufacturing Services (CRAMS) - Global Key Competitors Percentage Market Share in 2024 (E)
• Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)

MARKET TRENDS & DRIVERS

• Increased Outsourcing by Pharmaceutical Companies Boosts CRAMS Market
• Growing Demand for Biologics and Biosimilars Stimulating CRAMS Growth
• Rise of Generic Pharmaceuticals Amplifying CRAMS Opportunities
• Regulatory Changes and Compliance Requirements Shaping CRAMS Dynamics
• Advances in Manufacturing Technologies and Their Impact on CRAMS
• Expansion of CRAMS in Emerging Markets
• Strategic Alliances and Mergers Driving Market Consolidation
• Impact of Global Health Crises on CRAMS Demand
• Evolving Intellectual Property Laws and Their Influence on CRAMS
• Sustainability Trends and Their Adoption in CRAMS Facilities
• Digitalization and Automation Enhancing CRAMS Efficiency
• Patient-centric Drug Development and Its Effects on CRAMS
• Shift Towards Specialized Therapeutic Areas and Its Impact on CRAMS
• Venture Capital Funding and Its Influence on CRAMS Expansion
• Technological Innovations in Drug Development and Manufacturing

FOCUS ON SELECT PLAYERS: Some of the 86 companies featured in this report

• AbbVie Inc.
• Arch Pharmalabs Ltd.
• Calyx Chemicals and Pharmaceuticals Ltd.
• Globela Pharma Pvt. Ltd.
• Ind-Swift Laboratories Ltd.
• Merck KGaA,
• MSN Laboratories
• Murli Krishna Pharma Private Ltd.
• Novartis AG
• Orchid Pharma Ltd.
• SMS Pharmaceuticals Ltd.
• Sun Pharmaceutical Industries Ltd.
• Thermo Fisher Scientific Inc.
• Ultratech India Limited
• VIVAN Life Sciences Pvt Ltd.

For more information about this report visit

About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CONTACT: CONTACT: Laura Wood,Senior Press Manager ... For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

MENAFN08052025004107003653ID1109524768